Molecular Biology Professionals to Know 2025

Dr. James Utley is a pioneering scientist at the forefront of cellular therapy, AI, and data science. A Johns Hopkins-educated Immunohematology expert and Certified Advanced Biotherapies Professional (CABP), he also holds advanced certifications in data science and machine learning. While serving as Technical Director at a major healthcare organization, Dr. Utley oversaw more than 150,000 successful cellular transfusions and spearheaded advancements that significantly improved patient outcomes. This experience included leading initiatives for the Department of Defense, where he revolutionized cellular transfusion practices. His innovative approach is further exemplified by his FDA-approved work and numerous publications in leading scientific journals. Dr. Utley is also known for his bold, hands-on approach to research, embodying the spirit of a "biohacker" by pushing the boundaries of CRISPR and genetic engineering through self-experimentation. This unique blend of rigorous scientific training and unconventional methods has earned him the moniker "the pirate" within the biohacker community.

A PhD graduate of ETH Zurich in Food Microbiology, Dr. Mario Hupfeld became a member of the NEMIS Technologies co-founding team as CSO in 2018. He's lived and worked in Germany, UK, Italy and Switzerland, and developed 7 products from ideation to commercialization since NEMIS Technologies' inception.

Actively helping businesses to benefit from chatbots and voice assistants. Managing a chatbot company for the last 3 years: 100 chatbots built, 50 happy clients from 14 countries, 4 hackathons won with a chatbot idea, Company growth from 3 to 35 chatbot ninjas Working with Messenger API since April 2016 Rich experience with different platforms like FB messenger, Slack, SMS, Telegram, Cisco Spark, Web, Google Home, Amazon Alexa etc. I believe that chatbots are the new era of human/machine communication. I can help with the best practices of chatbot`s development, and it`s not only about the code but also about user engagement and profitability.

--- will be updated soon ---

Jorge Gandara immigrated from Guatemala to New York in 1992 at the age of seven and exhibited a high proficiency in math and science throughout his childhood. This talent and interest eventually led Mr. Gandara to pursue a Bachelor’s degree in Ecology & Evolutionary Biology and graduate in 2009 from Stony Brook University, where he also began his scientific career as a lab technician. Over the years, Jorge has held key roles in laboratories at prestigious institutions like Mirimus Inc., The Rockefeller University, and Dr. Christopher Mason’s lab at Weill Cornell Medicine, where he contributed to the PathoMAP project (now MetaSUB), mapping the DNA of every NYC subway station. In July of 2018, the Microbiome Core at Weill Cornell Medicine was established. Jorge built the Core from the ground up with a focus on high-throughput DNA processing, namely 16S Sequencing and Shotgun Metagenomic Sequencing. Since the Core’s inception, Jorge has overseen the processing of nearly 17,000 samples from notable institutions across the United States and internationally and was appointed the Microbiome Core Manager in January 2024. His expertise in advanced sequencing techniques and the Microbiome Core’s white glove sample service make it one of the most successful and unique facilities in the field.

Clinical trial management of two stem cell clinical trials. I have a passion for data science analytics and rigorous pattern-seeking. I believe in leading from the front and making sure the team is well taken care of. *Managing 2 stem cell clinical trials, NCT02838316 and NCT05421689*30 peer-reviewed publications.*>12,000 citations.*2 provisional patents.*Co-founded startup.*Co-developed departmental leadership program.*Strong track record of grant funding and collaboration building.* Associated Editor for two flagship scientific journals (Stem Cells, Journal of Extracellular Biology).GOOGLE SCHOLAR PROFILEhttps://scholar.google.com/citations?user=3uQtjEEAAAAJ&hl=en

NAYA Biosciences is building a group of companies leveraging the next generation of biotechnologies to increase patient access to life-transforming treatments in oncology, fertility,and auto-immune diseases . Our unique capabilities provide a synergistic platform for the accelerated clinical development and commercialization of these breakthrough therapies.Daniel Teper is a serial entrepreneur and a corporate strategist who has founded, led, and advised several biopharma companies both in the US and internationally. Daniel has a proven ability to identify and execute strategic partnerships, mergers and acquisitions, and financing deals that create value for all stakeholders. Daniel holds a PharmD degree from Université Paris-Saclay, an MBA from INSEAD, and completed executive programs at Wharton and MIT.

I am a Bioinformatician with extensive experience of analyzing Genomics and Transcriptomics data from Next Generation Sequencing Platforms. I enjoy designing, implementing and automating computational pipelines for Biological Data Analysis using multiple programming languages. I also possess over three years of experience working in wet lab with several Molecular Biology tools. I have worked as teaching assistant for both undergrads and grad students.I enjoy solving problems independently as well as by being part of a collaborative inter-disciplinary team.

Experienced and passionate Scientist with a demonstrated history of working in both basic and applied biological sciences. Skilled in immunology, inflammation, antibody-drug conjugates, diabetes, ageing research and tissue regeneration etc. Strong research professional with a Ph.D. (Magna Cum Laude) in Natural Sciences from the Max Planck Institute for Biology of Ageing in Köln, Germany and postdoctoral experience in Diabetes research from Helmholtz Diabetes Research Center in Munich, Germany. Currently, working on exciting projects to investigate mechanisms of inflammation, cellular plasticity, ADC-mediated cell depletion approach and regenerative processes within the context of homeostasis, disease and ageing at Genentech Inc., South San Francisco, USA.